Ardelyx Reported Lower Healthcare Use for IBSRELA
New real-world data shows reduced gastrointestinal visits for patients treated with the medication IBSRELA.
Updated on Oct. 12, 2026 in Healthcare
Live Poll
Do you trust that new medical treatments will reduce the long-term burden of your chronic conditions?
Ardelyx released results from a real-world analysis showing that patients with IBS-C who initiated treatment with IBSRELA saw a significant decrease in healthcare resource utilization. The findings were presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.
Why it matters
This real-world evidence suggests that treating chronic gastrointestinal conditions like IBS-C may lower the frequency of clinic visits, potentially reducing the burden on the healthcare system. These findings help clinicians better understand the long-term management benefits for the estimated 12 million people living with the condition in the United States.
The study analyzed 470 patients who initiated treatment with IBSRELA, finding a 33% reduction in median GI-related visits. Data indicates the medication works by inhibiting the sodium/hydrogen exchanger 3 to retain luminal water and accelerate transit time.
The players
Ardelyx
This biopharmaceutical company, headquartered in Waltham, Mass., focuses on the development of innovative medicines to treat cardiorenal and gastrointestinal diseases.
American College of Gastroenterology
This professional organization is dedicated to advancing the clinical practice of gastroenterology through medical education and research.
The details
Researchers at a national gastroenterology practice tracked patient outcomes, observing that median GI-related healthcare resource utilization fell from 4.5 to 3.0 visits following initiation of the drug. IBSRELA functions by reducing sodium absorption in the small intestine and colon to improve stool consistency.
Timeline
August 6, 2026: Ardelyx filed its Quarterly Report on Form 10-Q.
October 12, 2026: Data was presented at the ACG 2026 meeting.
October 13, 2026: Scheduled poster presentations occurred at the ACG 2026 meeting.
Market Landscape
This release positions Ardelyx within a competitive landscape of firms striving to prove that targeted therapies for IBS-C can reduce systemic healthcare costs. It reflects a broader trend where pharmaceutical companies emphasize real-world evidence to differentiate their products in the digestive health market.
Patients and providers can use this information to evaluate the potential impact of IBSRELA on reducing the number of clinical visits required for condition management. The data offers a pragmatic look at how shifting to this medication might affect patient healthcare utilization.
The takeaway
Real-world data is becoming an essential tool for demonstrating the broader utility of specialty medications in reducing systemic healthcare burdens. Patients should consult their gastroenterologists to discuss whether the clinical benefits of IBSRELA are appropriate for their personal health needs.
Further reading
For additional context on industry developments, visit the Healthcare section.
More information
To learn more about the company's research and products, visit the Ardelyx corporate website.
Live Poll
Do you trust that new medical treatments will reduce the long-term burden of your chronic conditions?
